NattoPharma’s (Oslo, Norway & East Brunswick, NJ) scientific leadership created the vitamin K2 category more than 20 years ago and has continued to shape the understanding of this nutrient’s benefits. As the research takes shape confirming vitamin K2’s expanding role supporting other overall health, NattoPharma has introduced its new logo, brand identity and website.
“Our science has always been a driver for brand owners to join with NattoPharma. Our MenaQ7 Vitamin K2 has been the source materials for more than 20 published human clinical trials with more underway, confirming bone and cardiovascular benefits,” said NattoPharma CEO Kjetil Ramsøy. “As we look to the future, we see nothing but promise and potential, particularly as the benefits of vitamin K2 are expanding, where again, we will lead in that discovery.”
While focusing on the scientific validation confirming that vitamin K2 safely and effectively improves health outcomes for adult and child populations, the NattoPharma brand has remained unchanged for almost two decades. Instead, the company said it has been focused on the success of its partners, ensuring they could deliver on the promise of better the health status of their customers with proven raw materials.
In addition to the new NattoPharma brand identity and the importance of vitamin K2 for bone and cardiovascular health, the site includes other significant enhancements that include:
- Why MenaQ 7 provides insight into why it is the vitamin K2 of choice for quality supplement manufacturers and how it is the most comprehensive K2 portfolio available to date.
- K2 Science expands the understanding of what is required to offer the industry’s only clinically validated vitamin K2 as MK-7, resulting in an unmatched patent portfolio.
- Partner portal provides a direct connection to the MenaQ7 Partner Site, created to give companies utilizing MenaQ7 access to the vast marketing collateral so they can impactfully communicate their product’s superiority.
For more information, www.nattopharma.com.